I am seeing a report:
Gilead Science’s experimental antiviral medicine remdesivir is reportedly showing promise for the treatment of people plagued with the novel coronavirus, with nearly all patients in a closely monitored clinical trial at a Chicago hospital discharged in just days, an early assessment of data released this week revealed . . . .
STAT, a medical news outlet, first reported that an early peek at the data from the clinical trial in Chicago suggested that coronavirus patients were responding to the Gilead Science drug.
“The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” Kathleen Mullane, the University of Chicago infectious disease specialist overseeing the remdesivir studies for the hospital, declared, according to STAT.
On Thursday, STAT revealed that the drug is prompting “rapid recoveries in fever and respiratory symptoms, with nearly all patients [at the Chicago hospital] discharged in less than a week,”
Of course, this is a leak. And of course due cautions apply. All of these developments fall under the strong reminder: pharmacology is the study of poisons in small doses. END